CSIMarket
 


Genetic Technologies Limited  (GENE)
Other Ticker:  
 

Genetic Technologies Limited's Working Capital Ratio

GENE's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




GENE Working Capital Ratio (Jun 30 2019)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Jun 30 2018)
IV. Quarter
Y / Y Current Liabilities Change 2.92 % 2.92 % 2.92 % 2.92 % -
Y / Y Current Assets Change -46.66 % -46.66 % -46.66 % -46.66 % -
Working Capital Ratio MRQ 2.14 2.14 2.14 2.14 4.13
Overall Ranking # # # # #
Seq. Current Liabilities Change 0 % 0 % 0 % 2.92 % 0 %
Seq. Current Assets Change 0 % 0 % 0 % -46.66 % 0 %



Working Capital Ratio forth quarter 2019 Comment
Regardless of the sequential decrease in Current Liabilities, Working Capital Ratio detoriated to 2.14 below company average Working Capital Ratio.

Within Biotechnology & Pharmaceuticals industry Genetic Technologies Limited booked the highest Working Capital Ratio than Genetic Technologies Limited in the forth quarter 2019. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is GENE most successful ?
Working Capital Ratio GENE on the trailing twelve month basis
Working Capital Ratio forth quarter 2019 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall Market # 0


Working Capital Ratio Statistics
High Average Low
4.13 3.13 2.14
(Jun 30 2018)   (Jun 30 2019)




Financial Statements
Genetic Technologies Limited's Current Liabilities $ 1 Millions Visit GENE's Balance sheet
Genetic Technologies Limited's Current Assets $ 3 Millions Visit GENE's Balance sheet
Source of GENE's Sales Visit GENE's Sales by Geography


Cumulative Genetic Technologies Limited's Working Capital Ratio

GENE's Working Capital Ratio for the trailling 12 Months

GENE Working Capital Ratio

(Jun 30 2019)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Jun 30 2018)
IV. Quarter
Y / Y Current Liabilities TTM Growth 2.92 % 2.92 % 2.92 % 2.92 % -
Y / Y Current Assets TTM Growth -46.66 % -46.66 % -46.66 % -46.66 % -
Working Capital Ratio TTM 2.14 2.63 3.12 3.62 4.13
Total Ranking TTM # # # # #
Seq. Current Liabilities TTM Growth 0 % 0 % 0 % 2.92 % 0 %
Seq. Current Assets TTM Growth 0 % 0 % 0 % -46.66 % 0 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis Due to unchange in Current Liabilities in the IV. Quarter to $1.49 millions, average cumulative Working Capital Ratio decreased to 2.14 below the Genetic Technologies Limited average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry GENE achieved the highest Working Capital Ratio. While overall ranking remained unchanged compare to previous quarter at no. 0.

Explain Working Capital Ratio
Where is GENE most successful ?
Working Capital Ratio GENE on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Within the Market # 0


TTM Working Capital Ratio Statistics
High Average Low
2.14 2.14 2.14
(Jun 30 2019)  




Companies with similar Working Capital Ratio in the quarter ending Jun 30 2019, within Biotechnology & Pharmaceuticals Industry Working Capital RatioJun 30 2019 MRQ Current AssetsJun 30 2019 MRQ Current Liabilities
Nanostring Technologies Inc   5.76 $ 190.117  Millions$ 32.986  Millions
Myomo Inc   5.76 $ 8.275  Millions$ 1.436  Millions
Solid Biosciences Inc   5.73 $ 78.321  Millions$ 13.671  Millions
Chase Corporation  5.63 $ 128.233  Millions$ 22.773  Millions
Sangamo Therapeutics Inc   5.63 $ 461.808  Millions$ 82.045  Millions
Fate Therapeutics Inc   5.61 $ 165.178  Millions$ 29.418  Millions
Protara Therapeutics Inc   5.59 $ 11.495  Millions$ 2.055  Millions
Spark Therapeutics Inc   5.56 $ 503.016  Millions$ 90.401  Millions
Volitionrx Limited  5.50 $ 19.244  Millions$ 3.498  Millions
Lakeland Industries Inc   5.49 $ 80.012  Millions$ 14.572  Millions
Eyepoint Pharmaceuticals Inc   5.46 $ 58.573  Millions$ 10.721  Millions
Lifeloc Technologies Inc   5.45 $ 5.516  Millions$ 1.012  Millions
Meiragtx Holdings Plc  5.22 $ 212.875  Millions$ 40.790  Millions
Quotient Limited  5.17 $ 115.441  Millions$ 22.335  Millions
Coherus Biosciences inc   5.07 $ 205.630  Millions$ 40.576  Millions
Bio rad Laboratories Inc   5.07 $ 2,087.940  Millions$ 412.044  Millions
Intuitive Surgical Inc   5.04 $ 4,071.600  Millions$ 807.500  Millions
Anavex Life Sciences Corp   5.03 $ 21.817  Millions$ 4.337  Millions
Scientific Industries Inc  5.00 $ 6.591  Millions$ 1.317  Millions
Central Garden and Pet Co  4.84 $ 1,349.626  Millions$ 278.813  Millions
Sutro Biopharma Inc   4.49 $ 162.223  Millions$ 36.099  Millions
Editas Medicine inc   4.45 $ 324.240  Millions$ 72.867  Millions
Bio techne Corp  4.44 $ 412.607  Millions$ 92.901  Millions
Cardiff Oncology inc   4.11 $ 11.820  Millions$ 2.878  Millions
Erytech Pharma S.a.  4.10 $ 91.373  Millions$ 22.267  Millions
Capstone Companies Inc   4.06 $ 4.575  Millions$ 1.126  Millions
Biontech Se  4.05 $ 627.369  Millions$ 154.719  Millions
Ocugen Inc   4.05 $ 3.200  Millions$ 0.791  Millions
Coherent Corp   3.97 $ 1,145.313  Millions$ 288.514  Millions
Natural Health Trends Corp   3.95 $ 124.576  Millions$ 31.528  Millions

Date modified: 2022-08-31T08:21:00+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SCLE's Profile

Stock Price

SCLE's Financials

Business Description

Fundamentals

Charts & Quotes

SCLE's News

Suppliers

SCLE's Competitors

Customers & Markets

Economic Indicators

SCLE's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071